Fort Washington Investment Advisors Inc. OH Grows Holdings in Stryker Co. (NYSE:SYK)

Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 14.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 5,476 shares of the medical technology company’s stock after purchasing an additional 707 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Stryker were worth $1,972,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of SYK. Dunhill Financial LLC increased its position in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Centennial Bank AR grew its stake in shares of Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the third quarter valued at approximately $36,000. Hara Capital LLC purchased a new stake in shares of Stryker during the third quarter worth approximately $42,000. Finally, HBW Advisory Services LLC purchased a new position in Stryker in the 3rd quarter valued at $42,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.8 %

SYK opened at $393.79 on Friday. The business’s fifty day simple moving average is $375.82 and its 200 day simple moving average is $360.16. Stryker Co. has a 52 week low of $307.23 and a 52 week high of $398.20. The firm has a market cap of $150.12 billion, a P/E ratio of 42.21, a PEG ratio of 2.72 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period in the previous year, the firm posted $2.46 earnings per share. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s dividend payout ratio (DPR) is 36.01%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SYK. JPMorgan Chase & Co. raised their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. UBS Group boosted their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Tuesday, January 7th. Finally, Robert W. Baird upped their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.